Michael Gelband’s Agios Pharmaceuticals AGIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-71,146
Closed -$1.94M 1514
2025
Q4
$1.94M Buy
+71,146
New +$2.5M 0.02% 779
2025
Q2
Sell
-10,553
Closed -$309K 1423
2025
Q1
$309K Buy
+10,553
New +$350K ﹤0.01% 1222
2024
Q2
Sell
-101,612
Closed -$2.97M 1477
2024
Q1
$2.97M Buy
101,612
+498
+0.5% +$13.3K 0.02% 559
2023
Q4
$2.25M Buy
+101,114
New +$2.27M 0.01% 543
2023
Q3
Sell
-120,363
Closed -$3.41M 1648
2023
Q2
$3.41M Sell
120,363
-78,003
-39% -$1.94M 0.03% 591
2023
Q1
$4.56M Buy
198,366
+184,341
+1,314% +$4.9M 0.04% 545
2022
Q4
$394K Buy
+14,025
New +$395K 0.01% 1266
2022
Q3
Sell
-60,238
Closed -$1.33M 1840
2022
Q2
$1.33M Sell
60,238
-106,221
-64% -$2.4M 0.02% 952
2022
Q1
$4.85M Buy
166,459
+155,287
+1,390% +$4.74M 0.06% 399
2021
Q4
$367K Sell
11,172
-13,806
-55% -$556K ﹤0.01% 1569
2021
Q3
$1.15M Buy
24,978
+21,016
+530% +$1.02M 0.02% 962
2021
Q2
$218K Sell
3,962
-64,711
-94% -$3.62M ﹤0.01% 1929
2021
Q1
$3.55M Sell
68,673
-2,928
-4% -$145K 0.05% 378
2020
Q4
$3.1M Buy
71,601
+41,829
+140% +$1.65M 0.03% 387
2020
Q3
$1.04M Sell
29,772
-30,136
-50% -$1.32M 0.02% 660
2020
Q2
$3.2M Buy
+59,908
New +$2.77M 0.08% 273
2019
Q2
Sell
-12,621
Closed -$851K 1068
2019
Q1
$851K Buy
+12,621
New +$735K 0.06% 216

Other funds holding AGIO

Michael Gelband's AGIO Position: Q1 2026 in Review

Michael Gelband sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 71,146 shares — an estimated $1.94M sold.

Michael Gelband first reported a position in AGIO in Q1 2019 and held it in 17 quarters. The position peaked at $4.85M in Q1 2022. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Michael Gelband reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 71,146 Agios Pharmaceuticals shares in Q1 2026, an estimated $1.94M.
  • Michael Gelband first reported a position in Agios Pharmaceuticals in Q1 2019 and held it in 17 quarters.
  • Michael Gelband's Agios Pharmaceuticals position peaked at $4.85M in Q1 2022.
  • 233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.